GW Pharmaceuticals PLC- (GWPH) Receives Consensus Recommendation of “Buy” from Analysts

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) have been assigned a consensus recommendation of “Buy” from the thirteen research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $147.38.

A number of brokerages have recently issued reports on GWPH. Goldman Sachs Group reissued a “neutral” rating and issued a $124.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Friday, October 6th. Bank of America reduced their price objective on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating for the company in a research report on Tuesday, November 14th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, November 20th. ValuEngine upgraded GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Evercore ISI assumed coverage on GW Pharmaceuticals PLC- in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 target price on the stock.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $124.49 on Friday. GW Pharmaceuticals PLC- has a 1-year low of $92.65 and a 1-year high of $136.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.26 and a current ratio of 10.39.

A number of hedge funds and other institutional investors have recently bought and sold shares of GWPH. Sterling Capital Management LLC acquired a new stake in GW Pharmaceuticals PLC- during the 3rd quarter worth about $254,000. Janney Montgomery Scott LLC purchased a new position in shares of GW Pharmaceuticals PLC- in the third quarter valued at about $650,000. Ladenburg Thalmann Financial Services Inc. lifted its position in GW Pharmaceuticals PLC- by 49.5% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,887 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 956 shares during the period. Cubist Systematic Strategies LLC lifted its position in GW Pharmaceuticals PLC- by 1,403.7% during the third quarter. Cubist Systematic Strategies LLC now owns 4,511 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 4,211 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in GW Pharmaceuticals PLC- by 19.2% during the third quarter. Point72 Asset Management L.P. now owns 158,343 shares of the biopharmaceutical company’s stock valued at $16,070,000 after purchasing an additional 25,543 shares during the period. 81.85% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “GW Pharmaceuticals PLC- (GWPH) Receives Consensus Recommendation of “Buy” from Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/01/gw-pharmaceuticals-plc-gwph-receives-consensus-recommendation-of-buy-from-analysts.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply